Healthcare

SINGAPORE (June 26): Clearbridge Health (CBH) is partnering Australia-based health information company Genome.One, a wholly-owned subsidiary of Garvan Institute of Medical Research, to offer its patients genomic testing and analysis with the latter’s Ge

SINGAPORE (May 24): Boustead Singapore announced that it is acquiring 100% of the shareholding of WhiteRock Incorporation (WRI), which comprises a group of 16 healthcare corporations operating in Singapore, China, Hong Kong, Malaysia and Thailand for $19

SINGAPORE (May 17): Hyphens Pharma International says its public offering of 3 million shares at 26 cents per share in conjunction with its Catalist listing was about 152 times subscribed.

SINGAPORE (May 2): HealthBaby Biotech (Hong Kong), a wholly-owned subsidiary of Cordlife Group, has launched a newborn metabolic screening service in Hong Kong.

SINGAPORE (May 2): RHB is downgrading its call on Raffles Medical Group (RMG) to “sell” from “neutral” with an unchanged $1.02 target price.

SINGAPORE (Apr 26): Hyphens Pharma International, the specialty pharmaceutical and consumer healthcare group which also owns the Ocean Health brand of supplements, has lodged a preliminary offer document with Singapore Exchange (SGX) to list on its Catali

SINGAPORE (Apr 26): On Feb 21, Cartier announced its selected 18 finalists from among 1,800 applications from over 130 countries, distinguished by the impact they are making in ensuring safe and dignified santitation; in improving healthcare and social ca

SINGAPORE (Mar 28): Singapore’s national customer satisfaction hit a new high in 2017, according to the 2017 Customer Satisfaction Index of Singapore (CSISG) released by the Institute of Service Excellence (ISE) at the Singapore Management University (S

SINGAPORE (Mar 6): Singapore O&G, the chain of medical practices specialising in women's health mainly in obstetrics and gynaecology (O&G), has agreed to a settlement amount of $1.25 million from its former lead independent director, Christopher Chong

SINGAPORE (Mar 1): UOB Kay Hian is maintaining its “buy” call on Singapore Medical Group (SMG) with a P/E-based target price of 83 cents, pegged to the peer average FY18 P/E ratio of 26.8 times.